Oric Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 3, 2026
ORIC$9.23+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-in · Accumulated · Accumulated Other Comprehensive · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balance at December 31, 2025 | 98,528,949 | $11 | $1,075,807 | $(692,242) | $786 | $384,362 |
| Issuance of common stock, net | 4,698,400 | — | 59,888 | — | — | 59,888 |
| Exercise of common stock options | 253,847 | — | 1,252 | — | — | 1,252 |
| Issuance of common stock upon vesting of RSUs | 5,216 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 6,898 | — | — | 6,898 |
| Unrealized loss on investments | — | — | — | — | (1,076) | (1,076) |
| Net loss | — | — | — | (35,767) | — | (35,767) |
| Balance at March 31, 2026 | 103,486,412 | $11 | $1,143,845 | $(728,009) | $(290) | $415,557 |
| Exercise of common stock options | 30,976 | — | 149 | — | — | 149 |
| Issuance of common stock upon vesting of RSUs | 13,093 | — | — | — | — | — |
| Issuance of common stock from ESPP | 105,943 | — | 679 | — | — | 679 |
| Stock-based compensation expense | — | — | 7,091 | — | — | 7,091 |
| Unrealized loss on investments | — | — | — | — | (728) | (728) |
| Net loss | — | — | — | (41,492) | — | (41,492) |
| Balance at June 30, 2026 | 103,636,424 | $11 | $1,151,764 | $(769,501) | $(1,018) | $381,256 |
| Common Stock · AdditionalPaid-in · Accumulated · Accumulated Other Comprehensive · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balance at December 31, 2024 | 71,021,855 | $7 | $805,510 | $(562,774) | $379 | $243,122 |
| Exercise of common stock options | 53,009 | — | 253 | — | — | 253 |
| Issuance of common stock upon vesting of RSUs | 3,647 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 6,554 | — | — | 6,554 |
| Unrealized loss on investments | — | — | — | — | (170) | (170) |
| Net loss | — | — | — | (30,021) | — | (30,021) |
| Balance at March 31, 2025 | 71,078,511 | $7 | $812,317 | $(592,795) | $209 | $219,738 |
| Issuance of common stock and pre-funded warrants, net | 14,980,313 | 2 | 133,267 | — | — | 133,269 |
| Exercise of common stock options | 7,812 | — | 34 | — | — | 34 |
| Issuance of common stock upon vesting of RSUs | 17,752 | — | — | — | — | — |
| Issuance of common stock from ESPP | 102,940 | — | 757 | — | — | 757 |
| Stock-based compensation expense | — | — | 6,574 | — | — | 6,574 |
| Unrealized loss on investments | — | — | — | — | (22) | (22) |
| Net loss | — | — | — | (36,355) | — | (36,355) |
| Balance at June 30, 2025 | 86,187,328 | $9 | $952,949 | $(629,150) | $187 | $323,995 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.